Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats

Behavioural Brain Research

Volumn 271, Issue , 2014, Pages 111-115

  Koike, Hiroyuki ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

AMPA receptor; Forced swim test; Ketamine; LY341495; MGlu2 3 receptor

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; KETAMINE; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; AMINO ACID; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; QUINOXALINE DERIVATIVE; XANTHENE DERIVATIVE;

AMPA RECEPTOR STIMULATION; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG MECHANISM; EXCITATORY SYNAPTIC TRANSMISSION; FORCED SWIM TEST; MALE; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; ADAPTIVE BEHAVIOR; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; MENTAL STRESS; METABOLISM; PSYCHOLOGY; SPRAGUE DAWLEY RAT; SWIMMING; TIME;

ADAPTATION, PSYCHOLOGICAL; AMINO ACIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; STRESS, PSYCHOLOGICAL; SWIMMING; TIME FACTORS; XANTHENES;

EID: 84902687924     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.05.065     Document Type: Article

References (28)

1. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
2. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71:939-946.
3. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
4. Mathew S.J., Murrough J.W., aan het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010, 13:71-82.
5. Salvadore G., Cornwell B.R., Sambataro F., Latov D., Colon-Rosario V., Carver F., et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010, 35:1415-1422.
6. Ibrahim L., Diazgranados N., Franco-Chaves J., Brutsche N., Henter I.D., Kronstein P., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012, 37:1526-1533.
7. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
8. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
9. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011, 224:107-111.
10. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
11. Fukumoto K., Iijima M., Chaki S. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology (Berl) 2014, (in press).
12. Dwyer J.M., Duman R.S. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry 2013, 73:1189-1198.
13. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011, 69:754-761.
14. Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012, 71:996-1005.
15. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46:457-467.
16. Karasawa J., Shimazaki T., Kawashima N., Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005, 1042:92-98.
17. Koike H., Iijima M., Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 2011, 61:1419-1423.
18. Koike H., Fukumoto K., Iijima M., Chaki S. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res 2013, 238:48-52.
19. Dwyer J.M., Lepack A.E., Duman R.S. mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int J Neuropsychopharmacol 2012, 15:429-434.
20. Liu R.J., Fuchikami M., Dwyer J.M., Lepack A.E., Duman R.S., Aghajanian G.K. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013, 38:2268-2277.
21. Ornstein P.L., Bleisch T.J., Arnold M.B., Kennedy J.H., Wright R.A., Johnson B.G., et al. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. J Med Chem 1998, 41:358-378.
22. Veilleux-Lemieux D., Castel A., Carrier D., Beaudry F., Vachon P. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. J Am Assoc Lab Anim Sci 2013, 52:567-570.
23. Svensson T.H. Low doses of atypical antipsychotic drugs added to selective serotonin inhibitors produce a ketamine-like facilitation of prefrontal glutamatergic neurotransmission. Int J Psychiatry Clin Pract 2013, 17(Suppl 2):6.
24. Akinfiresoye L., Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 2013, 230:291-298.
25. Yoshimizu T., Chaki S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 2004, 315:493-496.
26. Yuen E.Y., Liu W., Karatsoreos I.N., Feng J., McEwen B.S., Yan Z. Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory. Proc Natl Acad Sci U S A 2009, 106:14075-14079.
27. Yuen E.Y., Liu W., Karatsoreos I.N., Ren Y., Feng J., McEwen B.S., et al. Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. Mol Psychiatry 2011, 16:156-170.
28. Dwyer J.M., Lepack A.E., Duman R.S. mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry 2013, 1:15.